Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon plus suvorexant to prevent postoperative delirium after esophagectomy
jRCTs041220147Phase 2Active, not recruiting
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramelteon and suvorexant in esophageal cancer and postoperative delirium (POD). Primary endpoint: Incidence of postoperative delirium (CAM-ICU). Started Apr 2023; status: active, not recruiting.
02
Drugs
ramelteonsuvorexant
03
Conditions
esophageal cancerpostoperative delirium (POD)
Beyond the preview
Go deeper on jRCTs041220147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220147.